Prof. William Hope FRACP, FRCPA, PhD
Professor of Therapeutics & Infectious Diseases
Antifungal pharmacology, antifungal pharmacokinetics-pharmacodynamics, antifungal drug development
Professor Hope’s areas of special clinical interest and research are infections in immunocompromised patients, antimicrobial pharmacokinetics and pharmacodynamics, mathematical modelling of antimicrobial agents, population pharmacokinetics, and individualisation of antimicrobial therapy.
Professor Hope is Medical Guideline Director for the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), a member of the ICAAC Program Committee for Antimicrobial Pharmacokinetics (now Microbe) and a Council Member of the British Society for Antimicrobial Chemotherapy (BSAC).
Jason David Oliver, Graham E. M. Sibley, Nicola Beckmann, Katharine S. Dobb, Martin J. Slater, Laura McEntee, Joanne Livermore, Mike Bromley, Nathan P. Wiederhold, William Hope, Anthony J. Kennedy, Derek Law, and Mike Birch F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase Proc Natl Acad Sci U S A. 2016 Oct 25
Hope W, Drusano GL, Rex JH. Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality. J Antimicrob Chemother. 2016 Aug 5.
Al-Nakeeb Z, Petraitis V, Goodwin J, Petraitiene R, Walsh TJ, and Hope WW. 2015. Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus. Antimicrob Agents Chemother 59:2735–2745.
University of Liverpool